963 to 200 and Severe Pains Vanished.This is the story of a 72-year-old man from Surabaya, Indonesia. His prostate cancer had spread extensively to his back bone. I have the opportunity to meet with this patient in his house when we visited Surabaya. He benefited...
Garnick discussed the early treatment of metastatic prostate cancer, total androgen blockade, and the cost of 1 year of flutamide therapy. He stated that 165 000 new cases of prostate cancer are expected to be diagnosed in the United States in 1993, with 25% of patients presenting with stage...
Although avoiding or delaying a diagnosis of prostate cancer through chemoprevention is attractive, it is unknown whether 5ARI chemoprevention reduces the number of prostate cancer deaths. Prior cost–effectiveness studies have found the adoption of 5ARIs in the general population to not be cost ...
Cost- effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65.Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost‑effectiveness of prostate cancer chemoprevention: a quality of life‑years analysis. Cancer 2008; 112:...
Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis.Purpose Prostate cancer follow-up is traditionallydoi:10.1007/S00520-015-2857-8Alison M. Pearce AM Pearce,F Ryan,FJ Drummond,... - 《Supportive Care in Cancer Official Journal of the Multinational Ass...
Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC. We devised a treatment protocol consisting of...
A Response to Sher et al, "Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer" Sher DJ, Parikh R, Mays-Jackson S, et al: Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol [epub ... Collins, Sean P.,S Suy,Chen,...
Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate Journal of Clinical OncologyGu X, Choueiri TK, Martin NE, Hu JC, Nguyen PL. Overtreatment of low-risk prostate cancer in the United States: incidence, cost,...
32 The CAP trial provides a low-intensity benchmark against which other screening strategies can be compared in lifetime models of overdetection, overtreatment, and screening cost-effectiveness. This trial also identified the underdetection of lethal cancer in initial screening and among nonresponders ...
Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-023-00780-1. Altok M, Kim B, Patel BB, Shih Y-CT, Ward JF, McRae SE, et al. Cost and efficacy ...